Armen Shanafelt

Armen Shanafelt

President bij
Abshanafelt Advisory
66 jaar
Health Technology
Consumer Services
Finance

Profiel

Armen Shanafelt brings over 29 years of operational experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures.
Previous to joining Lilly Ventures in 2009, Armen held leadership and executive positions in the R&D organizations of DNAX Research Institute, Bayer Pharmaceuticals, Roche Diagnostics, and Eli Lilly and Company.
Armen currently serves as a director on the boards of Aeglea BioTherapeutics (NASDAQ: AGLE), Aileron Therapeutics (NASDAQ: ALRN), Protagonist Therapeutics (NASDAQ: PTGX), Surface Oncology (NASDAQ: SURF), Sutro Biopharma and Symic Biomedical.
He is a Kauffman Fellow (Class 14).
Armen received his B.S.
Degree in Chemistry and Physics from Pacific Lutheran University, and his Ph.D.
in Chemistry from the University of California, Berkeley.

Actieve functies van Armen Shanafelt

BedrijvenFunctieBegin
Abshanafelt Advisory
President 01-01-2021

Eerdere bekende functies van Armen Shanafelt

BedrijvenFunctieEinde
SURFACE ONCOLOGY, INC. Directeur/Bestuurslid 08-09-2023
SPYRE THERAPEUTICS, INC. Voorzitter 01-01-2019
Private Equity Investor 01-12-2020
REIN THERAPEUTICS INC. Directeur/Bestuurslid 19-06-2019
Directeur/Bestuurslid 01-06-2019
Ervaring van Armen Shanafelt in detail bekijken

Opleiding van Armen Shanafelt

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

61

Eerstegraads connecties

17

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit17

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Consumer Services

Health Technology

DNAX Research, Inc.

Health Technology

Health Technology

Abshanafelt Advisory

  1. Beurs
  2. Insiders
  3. Armen Shanafelt